SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Morepen Laboratories’ arm gets nod to form new subsidiary company

19 Feb 2025 Evaluate

Morepen Laboratories’ wholly owned subsidiary-- Dr. Morepen (DML) has received approval from Board of Directors for the formation of a new subsidiary company on February 19, 2025. The proposed entity will be named ‘Quick Med’ or any other name as approved by the Central Registration Centre, Ministry of Corporate Affairs (Proposed Company). 

Upon incorporation, the proposed company will become a step-down subsidiary of Morepen Laboratories. The proposed new company will operate in the pharmaceutical sector, specializing in the 'Online Retail Pharmacy' business.  

Morepen Laboratories is engaged in the manufacturing and sale of APis/ Bulk Drugs, Home Diagnostics, Formulations and OTC products. 


Morepen Laboratories Share Price

40.12 -0.06 (-0.15%)
13-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1652.00
Dr. Reddys Lab 1235.20
Cipla 1211.30
Zydus Lifesciences 923.10
Lupin 2312.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×